ReviewMedical2026
Cannabinoid Receptor Agonism with WIN 55,212-2 Differentially Reshapes Behavioral and Neurobiological Responses to Chronic Unpredictable Stress.
Celebi M.; Celebi C.; Aksoz E. · Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2026
Research summary
**Background & Methods**
This experimental study examined the effects of WIN 55,212-2, a non-selective cannabinoid receptor agonist, in 32 male Wistar rats exposed to chronic unpredictable mild stress (CUMS) over 35 days. Animals were divided into control, CUMS-only, WIN-only, and CUMS + WIN treatment groups, with behavioral assessments combined with measurement of circulating stress hormones (ACTH and corticosterone), brain redox markers, and mRNA expression analysis of neurotransmission and neuroplasticity genes.
**Key Findings**
• WIN 55,212-2 treatment attenuated anhedonia-like and anxiety-like behaviors induced by CUMS and improved stress-coping responses, while reducing elevated circulating ACTH and corticosterone levels, indicating HPA axis modulation.
• Cannabinoid receptor agonism produced selective mRNA expression changes: significant improvements in BDNF, CREB, 5-HT1B, and PSD-95 expression were observed in CUMS + WIN animals compared to untreated CUMS controls, whereas NMDA receptor, TrkB, and SLC1A2 expression showed no significant differences.
• The study demonstrated domain- and marker-dependent effects of cannabinoid agonism rather than uniform reversal of chronic stress pathology, with differential effects on behavioral, neuroendocrine, redox, and molecular parameters.
**Dosage & Administration**
WIN 55,212-2 was administered at 0.5 mg/kg/day via intraperitoneal injection during the final 21 days of the 35-day CUMS protocol.
**Safety & Adverse Effects**
Not reported.
**Evidence Quality**
This preclinical animal study provides mechanistic insight but has significant limitations regarding human translational relevance. The use of a single rat strain, male-only population, and specific stress paradigm limits generalizability. The differential effects across molecular markers suggest complex, non-uniform cannabinoid actions that require further investigation. The selective mRNA improvements without universal reversal of stress-induced changes indicate that cannabinoid receptor agonism may target specific neurobiological domains rather than broadly ameliorating chronic stress sequelae. Future studies should clarify which specific effects are therapeutically relevant and assess dose-response relationships and sex differences.
Summary generated by DeepWeed from the published abstract. See the original paper for full methods and results.
Journal
Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology
Ask how this study fits the wider evidence — across 26,000+ papers.
Ask DeepWeed
More recent cannabis research
This page summarises published research for informational purposes only — it isn't medical advice. Always refer to the original publication for full methods, results and limitations.